Open-label, Single-arm, Phase 1 Clinical Trial to Evaluate the Safety and Efficacy of Autologous TCR-T Cell Therapy in Subjects With Advanced Solid Tumors.

This document provides information about an ongoing clinical trial conducted by Tianjin Medical University Cancer Institute and Hospital in China. The trial, with the NCT number NCT06484790, aims to evaluate the safety and effectiveness of autologous TCR-T cell therapy in individuals with advanced solid tumors. Specifically, the trial focuses on the use of autologous anti-KRAS G12V/G12D mutation T-cell Receptor T cell in advanced solid tumors. The study is currently in the recruiting phase and is expected to be completed by April 2026. The trial is open to both male and female participants aged 18 to 75 and focuses on pancreatic cancer, colorectal cancer, and lung adenocarcinoma cancer. Contact information for the primary and backup contacts for the trial is also provided. [Extracted from the article]